The investigators plan to initiate a prospective, multicenter, phase II study, recruiting 30 patients with advanced colon cancer patients with liver metastasis who have not received prior treatment. This study plans to reconstruct intestinal microecology through fecal microbiota transplantation (FMT), and combine with QL1706+Bevacizumab+XELOX to enhance the anti-tumor immune effect at the same time, thereby improving the prognosis of colon cancer patients with liver metastasis.
Histological or cytological confirmed advanced colon cancer with liver metastasis.
Signed written informed consent.
Have not received anti-tumor treatment.
According to the investigators assessment, at least one measurable target lesion defined by RECIST v1.1.
Suffered from other malignancies in the past 5 years, excluding cured basal cell carcinoma of the skin, cervical carcinoma in situ and papillary thyroid carcinoma.
Patients requiring elective surgery during the trial.
Patients who cannot take oral drugs, or have conditions that the investigator determines to significantly affect gastrointestinal absorption, such as chronic diarrhea, intestinal obstruction, etc., and are not suitable for treatment.
Patients during pregnancy (positive pregnancy test) or lactation.
Hua Jiang
Lead sponsor
Changzhou No.2 People's Hospital
Sponsor institution